Literature DB >> 28076684

Radiographic Differentiation of Advanced Fibrocystic Lung Diseases.

Masanori Akira1.   

Abstract

The concept of end-stage lung disease suggests a final common pathway for most diffuse parenchymal lung diseases. In accordance with this concept, end-stage disease is characterized radiographically and pathologically by the presence of extensive honeycombing. However, sequential computed tomographic (CT) scans obtained from patients with chronic diffuse lung disease evolve over time to show various advanced lung disease patterns other than honeycombing. In addition, several radiographically distinct honeycomb patterns, including microcystic, macrocystic, mixed, and combined emphysema and honeycombing, differentiate one advanced lung disease from another. For example, usual interstitial pneumonia (IP) usually shows mixed microcystic and macrocystic honeycombing. In contrast, CT images of long-standing fibrotic nonspecific IP typically show only small, scattered foci of honeycombing; instead, most enlarged airspaces observed in the advanced stage of this disease represent dilatation of bronchioles. In desquamative IP and pulmonary Langerhans cell histiocytosis, focal opacities typically evolve into emphysema-like lesions seen on CT imaging. In combined pulmonary fibrosis and emphysema and sarcoidosis, the cysts tend to be larger than those observed in usual IP. Sequential CT scans in other chronic, diffuse lung diseases also show various distinctive changes. This article highlights radiographic patterns of lung destruction that belie a single common pathway to end-stage lung disease. Recognition of distinct radiographic patterns of lung destruction can help differentiate diffuse parenchymal lung diseases, even in advanced stages of disease evolution.

Entities:  

Keywords:  diffuse parenchymal lung disease; end-stage lung; high-resolution computed tomography; honeycombing; interstitial lung diseases

Mesh:

Year:  2017        PMID: 28076684     DOI: 10.1513/AnnalsATS.201611-883PS

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  5 in total

1.  Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease.

Authors:  Lee Fidler; Irena Doubelt; Sonja Kandel; Jolene H Fisher; Shikha Mittoo; Shane Shapera
Journal:  Lung       Date:  2019-03-05       Impact factor: 2.584

2.  Combined Pulmonary Fibrosis and Emphysema and Digital Clubbing.

Authors:  Taha F Rasul; Daniel R Bergholz; Randal Rovinski; Sana Gulraiz; Ernesto Fonts
Journal:  Cureus       Date:  2022-04-18

Review 3.  Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings.

Authors:  Tae Iwasawa; Tamiko Takemura; Takashi Ogura
Journal:  Jpn J Radiol       Date:  2017-12-15       Impact factor: 2.374

4.  Topographic heterogeneity of lung microbiota in end-stage idiopathic pulmonary fibrosis: the Microbiome in Lung Explants-2 (MiLEs-2) study.

Authors:  Eleanor Valenzi; Haopu Yang; John C Sembrat; Libing Yang; Spencer Winters; Rachel Nettles; Daniel J Kass; Shulin Qin; Xiaohong Wang; Michael M Myerburg; Barbara Methé; Adam Fitch; Jonathan K Alder; Panayiotis V Benos; Bryan J McVerry; Mauricio Rojas; Alison Morris; Georgios D Kitsios
Journal:  Thorax       Date:  2020-12-02       Impact factor: 9.139

Review 5.  Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis.

Authors:  Ashesh Chakraborty; Michal Mastalerz; Meshal Ansari; Herbert B Schiller; Claudia A Staab-Weijnitz
Journal:  Cells       Date:  2022-03-19       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.